This Phase 1b/2 open-label, dose escalation
study evaluates margetuximab, an Fc-optimized anti-HER2 monoclonal antibody, in combination with pembrolizumab, an anti-PD-1 antibody.
According to the companies, with both doses having been deemed safe, the MFDS has approved dose escalation
and an updated study design.
In the treatment of gout, dose escalation
of allopurinol to achieve target serum urate levels at or below 6 mg/ dL appears safe and effective, even among patients with chronic kidney disease, according to a new open-label, extension study.
Gradual dose escalation
of allopurinol achieved target serum urate levels without causing excess adverse effects in patients with gout who tolerated but responded inadequately to creatinine clearance-based dosing, including in patients with chronic kidney disease, investigators reported in Annals of the Rheumatic Diseases.
The lithium salt of GLA (LiGLA) can be administered intravenously and a dose escalation
study of a 10 day infusion followed by oral therapy in patients with inoperable pancreatic cancer was carried out in 48 patients in two centres.
The case is unique because the patient experienced an impressive and extremely rapid response to sunitinib dose escalation
to 50 mg/day delivered in continuous daily administration form, as opposed to the conventional dose of 50 mg/day for 4 of 6 weeks dosing on which the patient had a disease relapse.
A maximum of three cohorts will be enrolled in the REOLYSIN(R) dose escalation
Some experts recommend clinical and laboratory monitoring more often than once per month, and in particular, would include monitoring of liver function tests at baseline, prior to dose escalation
and at two weeks post dose escalation
But many people do not stop using cocaine once they start, and, he notes, "even if there is no dose escalation
, one becomes more vulnerable to seizures over time.
The trial is to start dose escalation
in healthy volunteers and graduate to patients when a predefined knockdown target is achieved.
EpiTan Limited [ASX: EPT], Melbourne, Australia, has announced better than expected efficacy in its implant dose escalation
trial which commenced in November 2003.